Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 09/27 03:35:01 pm
41.7301 USD   +0.12%
09/21 ABBOTT LABORATO : Malnutrition Adds $15.5 Billion Annually to Direct..
09/21DJABBOTT LABORATO : to Delist from London Stock Exchange
09/21 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Abbott Laboratories : Abbott and AbbVie Announce Investor Calls

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2013 | 04:10pm CEST

Abbott Park, Illinois and North Chicago - Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2012 financial results on Wednesday, Jan. 23, 2013, before the market opens.

Abbott's quarterly and annual results will include contributions from the company's former research-based pharmaceutical business, which became AbbVie on Jan. 1, 2013. While these results will be captured in a single press release, both companies will host separate conference calls to discuss their respective business results and 2013 outlooks.

Abbott will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) on Jan. 23, 2013. It will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

On Wednesday, Jan. 30, 2013, AbbVie will host a live webcast at 8 a.m. Central time (9 a.m. Eastern) accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Abbott Contacts:
Media:
Scott Stoffel

(847) 936-9502
Financial:
Brian Yoor

(847) 937-6343
AbbVie Contacts:
Media:
Adelle Infante

(847) 938-8745
Financial:
Larry Peepo

(847) 935-6722
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
09/21 ABBOTT LABORATORIES : Malnutrition Adds $15.5 Billion Annually to Direct U.S. Me..
09/21 DGAP-NEWS : Abbott Laboratories: Announcement of Intention to Delist
09/21DJABBOTT LABORATORIES : to Delist from London Stock Exchange
09/21 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
09/21 ABBOTT LABORATORIES : MILITARY $38,669 Federal Contract Awarded to Abbott Labora..
09/20 ABBOTT LABORATORIES : Justification and Approval - Abbott Laboratories Chemical ..
09/20 FUELING PERFORMANCE WITH FAT : EAS® Launches First Ketogenic Meal Replacement Fo..
09/19 ABBOTT LABORATORIES : Nippon Life Insurance Co Lowers stake in Abbott Laboratori..
09/17 JOHNSON & JOHNSON : to buy Abbott's vision unit for $4.3B
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Amazon's Next Step Toward Global Domination
09/22 JOHNSON & JOHNSON : From Dead Money To Amongst The Best In My Portfolio
09/21 Presenting Apple's First Car
09/20 A Unique Method To Value Dividend Stocks Based On Expected Growth
09/20 My Top Picks For Q4
Advertisement
Financials ($)
Sales 2016 20 939 M
EBIT 2016 3 925 M
Net income 2016 2 235 M
Debt 2016 2 699 M
Yield 2016 2,49%
P/E ratio 2016 23,33
P/E ratio 2017 18,03
EV / Sales 2016 3,05x
EV / Sales 2017 2,92x
Capitalization 61 269 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 47,8 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES-7.19%61 269
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results